Cerity Partners LLC Increases Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Cerity Partners LLC increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 29.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,793 shares of the medical research company's stock after acquiring an additional 1,767 shares during the quarter. Cerity Partners LLC's holdings in Bio-Rad Laboratories were worth $2,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also bought and sold shares of BIO. Capital Advisors Ltd. LLC grew its holdings in shares of Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock worth $26,000 after purchasing an additional 62 shares during the last quarter. UMB Bank n.a. grew its holdings in Bio-Rad Laboratories by 140.6% in the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Gladius Capital Management LP bought a new stake in Bio-Rad Laboratories in the 3rd quarter worth $32,000. Headlands Technologies LLC purchased a new position in shares of Bio-Rad Laboratories in the second quarter valued at about $51,000. Finally, Quarry LP bought a new position in shares of Bio-Rad Laboratories during the second quarter valued at about $59,000. 65.24% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Bio-Rad Laboratories

In other Bio-Rad Laboratories news, COO Andrew J. Last sold 3,000 shares of the business's stock in a transaction on Friday, September 6th. The stock was sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares of the company's stock, valued at approximately $2,494,016.46. The trade was a 28.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP James Barry sold 623 shares of the firm's stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the transaction, the executive vice president now owns 147 shares of the company's stock, valued at $48,582.03. The trade was a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Royal Bank of Canada raised their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an "outperform" rating in a research note on Thursday, October 31st. Citigroup lifted their price objective on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research report on Thursday, October 31st. StockNews.com raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company began coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories presently has an average rating of "Moderate Buy" and an average target price of $391.80.

Bio-Rad Laboratories Stock Up 0.6 %

Shares of NYSE:BIO traded up $2.05 during trading on Friday, hitting $340.53. The stock had a trading volume of 78,237 shares, compared to its average volume of 197,129. The company has a market capitalization of $9.53 billion, a PE ratio of -12.46 and a beta of 0.93. The company has a quick ratio of 4.52, a current ratio of 6.14 and a debt-to-equity ratio of 0.16. The firm's fifty day moving average is $340.77 and its 200 day moving average is $317.92. Bio-Rad Laboratories, Inc. has a 12 month low of $262.12 and a 12 month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million for the quarter, compared to analysts' expectations of $628.18 million. During the same period in the prior year, the firm earned $2.33 earnings per share. The firm's revenue for the quarter was up 2.8% on a year-over-year basis. Analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.